Xenon Pharmaceuticals Inc.·4

Sep 7, 4:26 PM ET

AULIN SHERRY 4

4 · Xenon Pharmaceuticals Inc. · Filed Sep 7, 2022

Insider Transaction Report

Form 4
Period: 2022-09-02
AULIN SHERRY
Chief Financial Officer
Transactions
  • Sale

    Common Shares

    2022-09-02$39.57/sh15,355$607,5970 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-028130 total
    Exercise: $8.40Exp: 2027-03-12Common Shares (813 underlying)
  • Exercise/Conversion

    Common Shares

    2022-09-02$9.44/sh+9,000$84,9609,000 total
  • Tax Payment

    Common Shares

    2022-09-02$39.53/sh3,293$130,17215,355 total
  • Exercise/Conversion

    Common Shares

    2022-09-02$3.10/sh+2,292$7,10512,137 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-02320 total
    Exercise: $7.49Exp: 2026-03-10Common Shares (32 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-026,5110 total
    Exercise: $4.75Exp: 2028-03-11Common Shares (6,511 underlying)
  • Exercise/Conversion

    Common Shares

    2022-09-02$7.49/sh+32$2409,032 total
  • Exercise/Conversion

    Common Shares

    2022-09-02$8.40/sh+813$6,8299,845 total
  • Exercise/Conversion

    Common Shares

    2022-09-02$4.75/sh+6,511$30,92718,648 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-029,0000 total
    Exercise: $9.44Exp: 2029-09-15Common Shares (9,000 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2022-09-022,2920 total
    Exercise: $3.10Exp: 2027-10-22Common Shares (2,292 underlying)
Footnotes (3)
  • [F1]Represents the closing price of the Company's common shares on September 1, 2022 for purposes of net settlement calculations.
  • [F2]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.63, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F3]The shares subject to the option are fully vested and exercisable.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION